🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

After many years of hard work starting in 2014, we present Step 1 of #PDIGREE presented by Tian Zhang, MD, MHS in advanced RCC ! 1100 patients and 400+ sites ! #ASCO25 ASCO Alliance for Clinical Trials in Oncology

📢 #ASCO25 | AREN1721 Ph. II | tRCC Trial: Nivo + axi (6 pts) in advanced tRCC: PR 33% vs 0% in mono arms (2pts axi and 5 nivo); With axitinib addition PFS increased from 1.8 → 10.5 mo , OS improved as well. 9/13 age < 18 years. No unexpected toxicities. Rare but aggressive

📢 #ASCO25 | ENLIGHTED Ph. III | Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC). Great session by Dr. #VitalyMargulis from UT Southwestern Urology discussing another

📢 #ASCO25 | CREST Ph. III | CIS/T1 Subgroups: Sasanlimab + BCG (Ind & Maint) vs BCG in high-risk NMIBC: 36-mo EFS in 176 pts with CIS and w/ and w/o papillary tumors 83.0% vs 71.8% (HR 0.53), 398 pts with T1 w/ and w/o CIS 81.3% vs 72.2% (HR 0.63). Tom Powles et al. Full

📢 #ASCO25 | STELLAR-002 Ph. Ib | Expansion: 1L zanza (XL092 = multi-targeted TKI of VEGFR, MET, and TAM kinases) + nivo in adv/met ccRCC: ORR 63% (4 CR, 21 PR), DCR (CR+PR+SD) 90%; 12-mo PFS 83.2. Zanza + nivo/rela (fixed-dose combo): ORR 33%, DCR 90% with manageable G3/4 AEs;

📢 #ASCO25 | Investigator-initiated Ph. I | Abemaciclib window of opportunity (CDK4-6 Inh) Pre-RC in MIBC – Abema before cystectomy: pCR 18.8%, downstaging 31.3%; on-target activity reduction in RB1-p, ctDNA showed tumor fraction reduction by 28.6%. Well-tolerated (G3 anemia 20%,

📢 #ASCO25 | SURE-02 Ph. II | Interim Results – SG + Pembro in CT-ineligible MIBC (n=40): cCR 38.7% (bladder preserved ~40%), ypT≤1 rate 51.6%; G≥3 AEs 12.9%. Luminal/GU tumors show highest ypT0; stromal signature linked to non-response. Insightful work by Andrea Necchi et al.

📢 #ASCO25 | NEOAVAX Ph II | High‐risk localized RCC: Neoadjuvant avelumab + axitinib × 12 wks pre‐nephrectomy in 40 pts: 30% ORR (12/40 PR), 20% median tumor downsizing; among responders, 10/12 were disease‐free at 23.5 mo median FU; no primary tumor progression.

📢 #ASCO25 | IMmotion010 Ph III | 778 pts high‑risk localized RCC: Adjuvant atezolizumab vs placebo—median DFS 57.2 mo vs 49.5 mo (HR 0.93; P = 0.50). Genomic analysis: baseline tumors from relapsing pts had ↑tumor mutational burden and PD‑L1 expression;

📢 #ASCO25 | CM 9ER Biomarker Analysis | 651 pts aRCC: Integrative analysis of circulating (e.g., early ctDNA clearance, peripheral immune subsets) & TME (CD8+ TIL density, PD‑L1 expression) determinants of response to NIVO+CABO. High baseline CD8+ TILs & ctDNA clearance

📢 #ASCO25 | CheckMate 901 | Cis‑ineligible mUC: NIVO 1 mg/kg + IPI 3 mg/kg Q3W×4→NIVO 480 mg Q4W vs gem‑carbo Q3W×6: Any‑grade TRAEs 89% (G3–4 47%) vs 93% (G3–4 76%); TRAE‑related discontinuation 31% vs 14%; 8 toxicity‑related deaths (7 vs 1); no OS benefit in

📢 #ASCO25 | JAVELIN Bladder Medley Ph II | aUC 1L maintenance: Avelumab + SG vs Avelumab alone—median PFS 11.17 mo vs 3.75 mo (HR 0.49; 95% CI 0.31–0.76); any‑grade TRAEs 97.3% vs 63.9%, G≥3 54.8% vs 17.9%. Jeannie Hoffman‑Censits et al. Full abstract

📢 #ASCO25 | EV‑302 Ph III | la/mUC Responders: Among pts achieving cCR, EV + P arm showed 74% 2‑yr maintained cCR vs 32% with chemo; median OS in responders was 33.8 mo vs 16.1 mo (HR 0.51; P<0.001). Shilpa Gupta et al. Full abstract → meetings.asco.org/abstracts-pres…

📢 #ASCO25 | NIAGARA ctDNA Analysis | MIBC pts on perioperative durvalumab: Baseline ctDNA+ in a subset linked to shorter EFS; early ctDNA clearance after D associated with improved DFS; persistent ctDNA post-surgery predicted relapse. Thomas Powles et al. Full abstract →

📢 #ASCO25 | ANZUP 1301 Ph III | HR NMIBC (~500 pts): Mitomycin + BCG vs BCG alone—combination arm met primary endpoint with significant DFS benefit (HR 0.70; 2‑yr DFS 78% vs 65%); recurrence reduced. Dickon Hayne et al. Full abstract → asco.org/abstracts-pres…

.Toni Choueiri, MD takes the stage to present data from the phase 1 ARC-20 trial that shows that the combination of HIF2 inhibitor casdatifan plus cabo has promising clinical activity (cORR 46%) and an acceptable safety profile in pretreated pts w/ mRCC. #ASCO25 ASCO OncoAlert

👉🏻 Our very own Chadi Hage Chehade presenting ASCO a real-world study showing most patients do not undergo NGS testing, and a substantial proportion receive it only near end of life—limiting its clinical utility and impact on treatment decisions. #ASCO25 GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO

🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 OncoAlert Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️

Fascinating data straight from 🇧🇷 with amazing oncologist and colleague Pablo Moura Barrios about different treatment patterns in private vs public settings #ASCO25 OncoAlert

📢 #ASCO25 | Major advance in mCRPC with bone mets by the one and only Rana McKay, MD, FASCO | Olaparib + Ra-223 vs Ra-223 Alone Ph. II | In a randomized study n=120, this combo doubled rPFS (8.6 vs 4.0 mo; HR 0.51) in both HRR-mut and HRR-wt patients — with manageable safety. A